Grade 3 BRCA2 carriers had received more often adjuvant chemotherapy or combined chemo-endocrine therapy than grade 2 patients (Supplementary Table 4), and the underlying differences in therapeutic practices for grade 2 and grade 3 ER-positive cancers may have contributed to the nominally lower survival of the grade 2 patients. Here, BRCA2 is linked to cancer.